Loading...
Verona Pharma plc
VRNA•NASDAQ
Healthcare
Biotechnology
$104.86
$0.09(0.09%)
Verona Pharma plc (VRNA) Financial Performance & Statements
Review Verona Pharma plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-127.96%
↓ 127.96%
Net Income Growth
-218.96%
↓ 218.96%
Operating Cash Flow Growth
-143.33%
↓ 143.33%
Operating Margin
-116.27%
↓ 116.27%
Gross Margin
94.72%
↑ 94.72%
Net Profit Margin
-138.37%
↓ 138.37%
ROE
-89.89%
↓ 89.89%
ROIC
-29.36%
↓ 29.36%
Verona Pharma plc (VRNA) Financial Statements
Explore quarterly and annual reports for Verona Pharma plc stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $76.26M | $36.66M | $5.62M | $0.00 |
| Cost of Revenue | $3.41M | $2.04M | $543000.00 | $270302.00 |
| Gross Profit | $72.85M | $34.62M | $5.08M | -$270302.00 |
| Gross Profit Ratio | $0.96 | $0.94 | $0.90 | |
| R&D Expenses | $14.05M | $7.87M | $10.55M | $19.41M |
| SG&A Expenses | $69.11M | $45.09M | $35.20M | $48.82M |
| Operating Expenses | $83.17M | $52.95M | $45.75M | $68.23M |
| Total Costs & Expenses | $86.57M | $54.99M | $46.29M | $68.50M |
| Interest Income | $3.89M | $3.99M | $4.75M | $3.14M |
| Interest Expense | -$10.20M | $10.32M | $9.88M | $1.76M |
| Depreciation & Amortization | $0.00 | $259000.00 | $268728.00 | $270302.00 |
| EBITDA | -$10.32M | -$82.21M | -$34.53M | -$53.24M |
| EBITDA Ratio | -$0.14 | -$2.24 | -$6.14 | |
| Operating Income | -$10.32M | -$18.34M | -$40.67M | -$68.50M |
| Operating Income Ratio | -$0.14 | -$0.50 | -$7.23 | |
| Other Income/Expenses (Net) | -$6.24M | -$7.22M | -$2.04M | -$15.69M |
| Income Before Tax | -$16.56M | -$25.56M | -$42.71M | -$70.75M |
| Income Before Tax Ratio | -$0.22 | -$0.70 | -$7.59 | |
| Income Tax Expense | $239000.00 | $8.27M | $250000.00 | $167187.00 |
| Net Income | -$16.32M | -$33.83M | -$42.96M | -$70.91M |
| Net Income Ratio | -$0.21 | -$0.92 | -$7.64 | |
| EPS | -$0.02 | -$0.05 | -$0.07 | -$0.11 |
| Diluted EPS | -$0.02 | -$0.05 | -$0.07 | -$0.11 |
| Weighted Avg Shares Outstanding | $679.40M | $652.31M | $651.94M | $648.22M |
| Weighted Avg Shares Outstanding (Diluted) | $679.40M | $652.31M | $651.94M | $648.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan